EUVIMEDEUVIMED entdecken
Open Access

Adequacy of cefepime concentrations in the early phase of critical illness: A case for precision pharmacotherapy

Erin F Barreto iD, Jack Chang, Matthew W Bjergum, Ognjen Gajic, Paul J Jannetto, Kristin C Mara, Laurie A Meade, Andrew D Rule, Kathryn J Vollmer, Marc H Scheetz iD, BLOOM Study Group

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2023-11 · 43 (11) · 1112-1120

DOI: 10.1002/phar.2766 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, online erschienen am 02.02.2023. Verfasst von Erin F Barreto und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Critical Illness, Pseudomonas Infections. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study Objective In critically ill patients, adequacy of early antibiotic exposure has been incompletely evaluated. This study characterized factors associated with inadequate cefepime exposure in the first 24 h of critical illness.

Design

Prospective cohort study.

Setting

Academic Medical Center. Patients Critically ill adults treated with cefepime. Patients with acute kidney injury or treated with kidney replacement therapy or extracorporeal membrane oxygenation were excluded.

Intervention

None.

Measurements

A nonlinear mixed‐effects pharmacokinetic (PK) model was developed to estimate cefepime concentrations for each patient over time. The percentage of time the free drug concentration exceeded 8 mg/L during the first 24 h of therapy was calculated (%ƒT>8; appropriate for the susceptible breakpoint for Pseudomonas aeruginosa ). Factors predictive of low %ƒT>8 were explored with multivariable regression. Main Results In the 100 included patients, a one‐compartment PK model was developed with first‐order elimination with covariates for weight and estimated glomerular filtration rate based on creatinine and cystatin C (eGFRSCr‐CysC). The median (interquartile range) %ƒT>8 for cefepime in the first 24 h of therapy based on this model was 85% (66%, 100%). Less than 100% ƒT>8 during first 24 h of therapy occurred in 70 (70%) individuals. Lower Sequential Organ Failure Assessment score ( p = 0.032) and higher eGFRSCr‐CysC ( p < 0.001) predicted a lower %ƒT>8. Central nervous system infection source was protective (i.e., associated with a higher %ƒT>8; p = 0.008).

Conclusions

During early critical illness, cefepime concentrations were inadequate in a significant proportion of patients. Antimicrobial optimization is needed to improve the precision of pharmacotherapy in the critically ill patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Critical IllnessPseudomonas InfectionsAdultHumansCefepimeProspective StudiesAnti-Bacterial AgentsMicrobial Sensitivity Tests

Stichwörter der Autor:innen

beta-lactamscritical careglomerular filtration ratepharmacokineticssepsis

Substanzen

CefepimeAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Pharmacy Practice, Chicago College of Pharmacy, Pharmacometrics Center of Excellence, Midwestern University, Downers Grove, Illinois, USA.
  • Department of Pharmacy, Northwestern Medicine, Chicago, Illinois, USA.
  • Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Pulmonary Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Erin F Barreto, Marc H Scheetz

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Barreto, E. F., Chang, J., Bjergum, M. W., Gajic, O., Jannetto, P. J., Mara, K. C., Meade, L. A., Rule, A. D., Vollmer, K. J., Scheetz, M. H., & BLOOM Study Group (2023). Adequacy of cefepime concentrations in the early phase of critical illness: A case for precision pharmacotherapy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 43(11), 1112-1120. https://doi.org/10.1002/phar.2766

Vancouver

Barreto EF, Chang J, Bjergum MW, Gajic O, Jannetto PJ, Mara KC, et al. Adequacy of cefepime concentrations in the early phase of critical illness: A case for precision pharmacotherapy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023;43(11):1112-1120. doi:10.1002/phar.2766

BibTeX
@article{Barreto2023,
  author = {Barreto, Erin F and Chang, Jack and Bjergum, Matthew W and Gajic, Ognjen and Jannetto, Paul J and Mara, Kristin C and Meade, Laurie A and Rule, Andrew D and Vollmer, Kathryn J and Scheetz, Marc H and BLOOM Study Group, BLOOM Study Group},
  title = {Adequacy of cefepime concentrations in the early phase of critical illness: A case for precision pharmacotherapy},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2023},
  volume = {43},
  number = {11},
  pages = {1112--1120},
  doi = {10.1002/phar.2766}
}
Kostenlos starten →